MedTech Diligence Now Has to Read Change Plans, Not Just Technical Files

MedTech Diligence Now Has to Read Change Plans, Not Just Technical Files

A technical file used to be a snapshot. A manufacturer built it, a notified body reviewed it, and it stayed fixed until the next update cycle. That model is breaking down for AI-enabled devices, and it is breaking down at the exact moment MedTech M&A diligence teams are learning to read technical files closely for the first time.

The underlying regulatory system is already under strain. The transition from MDD and IVDD to full MDR and IVDR remains what industry observers call a “rocky road,” with reform proposals, a 2027 target timeline, and notified body capacity all still in flux, according to healthcare-in-europe.com. A target company’s certification status is not a fact a buyer verifies once. It is a position inside a system still being rebuilt.

AI adds a second axis of complexity on top of that. Regulators, through IMDRF, have laid out key principles for adopting predetermined change control plans, or PCCPs, which let manufacturers pre-authorize specific future modifications to an AI-enabled device without a full resubmission each time the model changes, per RAPS. That is a meaningful efficiency gain for manufacturers. It also means the technical file itself now has to document a governance process for change, not just the device as it exists on submission day. Diligence on an AI-enabled device is diligence on a moving target with its own documented rules for how it is allowed to move.

The stakes of getting that documentation right are highest where AI is doing diagnostic or biomarker-driven work. Regulatory science for AI-based software as a medical device in computational pathology and biomarker-driven drug development is still being worked out in real time, with documentation standards forming around use cases that did not exist when MDR and IVDR were drafted, according to research published in PMC. Manufacturers are responding with dedicated workflow tooling built specifically to help regulatory teams assemble and maintain this class of documentation, as described in MedDeviceGuide’s review of Pure Global AI’s regulatory workflow tools.

NGeneBio’s recent CE-IVDR certification for its hereditary breast and ovarian cancer diagnostic panel, reported by Asia Business Daily, shows what a completed file still buys commercially: the company is using it explicitly as a springboard for European and Asian market expansion. That is the payoff. It is also a reminder that certification without a change control story is only half the picture once AI is inside the device.

Buyers are already treating MDR and IVDR technical files, clinical evaluation reports, and post-market surveillance data as deal-relevant rather than procedural, per the Acquisition Readiness Checklist, and industry framing increasingly treats genuine regulatory completeness as a source of competitive advantage rather than pure cost, per the European HealthTech Buy and Build Strategy Report. What neither captures yet is the PCCP layer. For any target where the device or diagnostic includes an adaptive AI component, the diligence question is no longer just whether the file is complete. It is whether the file discloses, and constrains, how the AI is allowed to change next.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that PCCPs create a new diligence layer beyond static technical files—is coherent and logically constructed, but the piece overstates its novelty claim in the final paragraph by asse
Source & Claim Verification	Qwen · local	cleared. All factual claims are supported by citations, but some sources could be more specific or recent to fully validate the claims.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the regulatory shift toward PCCPs under ISO 42001, EU AI Act, and FDA/MDR/IVDR frameworks, but lacks explicit mapping to specific clauses or requirements.
Technical Accuracy	Llama	cleared. The article accurately describes the evolving regulatory landscape for AI-enabled medical devices, including the role of predetermined change control plans (PCCPs) and the implications for MedTech M&A
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and addresses potential vendor hype by focusing on the practical implications of regulatory changes and the need for robust diligence, rather than uncritically prom
Novelty & Non-Duplication	Grok	held. Useful synthesis that explicitly adds a PCCP/change-plan diligence layer to the outlet’s own prior acquisition-readiness and buy-build pieces rather than duplicating any single prior item, though ever
Validation	DeepSeek	cleared. The central claim that diligence must now examine change control plans for AI-enabled devices is validated by the IMDRF principles for PCCPs, which explicitly shift documentation from a static snapsho

Sources cited: 15. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.